Medicenna Therapeutics Corp - Asset Resilience Ratio

Latest as of September 2025: 87.29%

Medicenna Therapeutics Corp (MDNA) has an Asset Resilience Ratio of 87.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MDNA current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CA$15.75 Million

≈ $11.39 Million USD Cash + Short-term Investments

Total Assets

CA$18.04 Million

≈ $13.05 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Medicenna Therapeutics Corp's Asset Resilience Ratio has changed over time. See Medicenna Therapeutics Corp net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Medicenna Therapeutics Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MDNA market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$15.75 Million	87.29%
Short-term Investments	CA$0.00	0%
Total Liquid Assets	CA$15.75 Million	87.29%

Asset Resilience Insights

Very High Liquidity: Medicenna Therapeutics Corp maintains exceptional liquid asset reserves at 87.29% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Medicenna Therapeutics Corp Industry Peers by Asset Resilience Ratio

Compare Medicenna Therapeutics Corp's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Argen-X F:1AE	Biotechnology	25.67%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.21%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.48%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	70.49%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for Medicenna Therapeutics Corp (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Medicenna Therapeutics Corp.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	87.51%	CA$24.84 Million ≈ $17.97 Million	CA$28.38 Million ≈ $20.53 Million	-1.24pp
2024-03-31	88.75%	CA$16.98 Million ≈ $12.28 Million	CA$19.13 Million ≈ $13.84 Million	-3.43pp
2023-03-31	92.18%	CA$33.60 Million ≈ $24.30 Million	CA$36.45 Million ≈ $26.36 Million	+4.63pp
2022-03-31	87.55%	CA$20.54 Million ≈ $14.85 Million	CA$23.46 Million ≈ $16.97 Million	-8.03pp
2021-03-31	95.58%	CA$40.38 Million ≈ $29.21 Million	CA$42.25 Million ≈ $30.56 Million	-3.64pp
2020-03-31	99.22%	CA$37.70 Million ≈ $27.27 Million	CA$38.00 Million ≈ $27.49 Million	+53.51pp
2019-03-31	45.71%	CA$2.37 Million ≈ $1.72 Million	CA$5.19 Million ≈ $3.75 Million	-44.33pp
2018-03-31	90.04%	CA$3.94 Million ≈ $2.85 Million	CA$4.37 Million ≈ $3.16 Million	-6.89pp
2017-03-31	96.93%	CA$14.04 Million ≈ $10.15 Million	CA$14.48 Million ≈ $10.48 Million	--

pp = percentage points

About Medicenna Therapeutics Corp

TO:MDNA Canada Biotechnology

Market Cap

$36.81 Million

CA$50.88 Million CAD

Market Cap Rank

#22994 Global

#843 in Canada

Share Price

CA$0.61

Change (1 day)

+3.39%

52-Week Range

CA$0.57 - CA$1.64

All Time High

CA$7.00